Therapeutic Plasma Exchange, Rituximab and IV Ig for Severe Acute Exacerbation of IPF Admitted in ICU | MicrobiomeTrials← Back to trialsNCT03584802
Therapeutic Plasma Exchange, Rituximab and IV Ig for Severe Acute Exacerbation of IPF Admitted in ICU
TERMINATEDNAINTERVENTIONAL
Trial Details
Start: 2019-05-16Est. Completion: 2019-11-15
Enrollment target: 5 participants Locations- Hôpital Bichat Claude Bernard, Paris, France
Other microbiome trials you might be interested in
Idiopathic Pulmonary Fibrosis
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and effic…
La Mesa, United StatesEst. completion Jan 2028
Fibrosing Interstitial Lung Disease
This study is open to children and adolescents aged 2 to 17 years with interstitial lung disease (ILD). Nerandomilast ha…
Los Angeles, United StatesEst. completion Apr 27, 2029
Recruiting
Idiopathic Pulmonary FibrosisAcute Exacerbation of Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by progressive scarring. Sometimes, patients…
Multiple LocationsEst. completion Sep 2027